WO1999065461A3 - Complexes micellaires d'amphiphiles cationiques - Google Patents

Complexes micellaires d'amphiphiles cationiques Download PDF

Info

Publication number
WO1999065461A3
WO1999065461A3 PCT/US1999/013875 US9913875W WO9965461A3 WO 1999065461 A3 WO1999065461 A3 WO 1999065461A3 US 9913875 W US9913875 W US 9913875W WO 9965461 A3 WO9965461 A3 WO 9965461A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
cells
active molecules
micellar complexes
molecule
Prior art date
Application number
PCT/US1999/013875
Other languages
English (en)
Other versions
WO1999065461A2 (fr
WO1999065461A9 (fr
Inventor
Jennifer D Tousignant
Simon J Eastman
Quiming Chu
Edward R Lee
Shaona L Fang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CA002335638A priority Critical patent/CA2335638A1/fr
Priority to AU46984/99A priority patent/AU4698499A/en
Priority to JP2000554341A priority patent/JP2002518313A/ja
Priority to EP99930442A priority patent/EP1085857A2/fr
Publication of WO1999065461A2 publication Critical patent/WO1999065461A2/fr
Publication of WO1999065461A3 publication Critical patent/WO1999065461A3/fr
Publication of WO1999065461A9 publication Critical patent/WO1999065461A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'introduction efficace de gènes étrangers et autres molécules biologiquement actives dans des cellules cible de mammifères reste un défi pour les scientifiques de la profession. La thérapie génique, par exemple, nécessite la transfection réussie de cellules cible chez un patient. La présente invention concerne de nouveaux complexes micellaires de composés amphiphiles cationiques favorisant l'apport de molécules biologiquement actives aux cellules cibles chez un mammifère. Ces nouveaux complexes micellaires comprennent un amphiphile cationique, une molécule biologiquement active, un dérivé du polyéthylène glycol, et éventuellement, un co-lipide. Un autre aspect de l'invention concerne l'utilisation d'agents cible dans n'importe quel procédé permettant l'apport de molécules biologiquement actives dans les cellules de mammifères. Un agent cible est, de façon générale, n'importe quelle molécule, séquence peptidique ou protéine de grande taille ciblant ou se liant de préférence à des cellules de mammifères spécifiques.
PCT/US1999/013875 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques WO1999065461A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002335638A CA2335638A1 (fr) 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques
AU46984/99A AU4698499A (en) 1998-06-19 1999-06-18 Cationic amphiphile micellar complexes
JP2000554341A JP2002518313A (ja) 1998-06-19 1999-06-18 カチオン性両親媒性ミセル複合体
EP99930442A EP1085857A2 (fr) 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8987998P 1998-06-19 1998-06-19
US60/089,879 1998-06-19

Publications (3)

Publication Number Publication Date
WO1999065461A2 WO1999065461A2 (fr) 1999-12-23
WO1999065461A3 true WO1999065461A3 (fr) 2000-02-24
WO1999065461A9 WO1999065461A9 (fr) 2001-02-01

Family

ID=22220044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013875 WO1999065461A2 (fr) 1998-06-19 1999-06-18 Complexes micellaires d'amphiphiles cationiques

Country Status (5)

Country Link
EP (1) EP1085857A2 (fr)
JP (1) JP2002518313A (fr)
AU (1) AU4698499A (fr)
CA (1) CA2335638A1 (fr)
WO (1) WO1999065461A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
JP5117648B2 (ja) * 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア カチオン性ｐｅｇ脂質および使用方法。
WO2001080900A2 (fr) * 2000-04-20 2001-11-01 The University Of British Columbia Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
JP4590519B2 (ja) * 2006-09-22 2010-12-01 独立行政法人産業技術総合研究所 腸管吸収制御性リポソーム
CN102065901B (zh) * 2008-06-19 2013-03-06 日本新药株式会社 药物载体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019738A1 (fr) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Methode de traitement de tissus infectes
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1996014864A1 (fr) * 1994-11-09 1996-05-23 The Regents Of The University Of California Immunoliposomes optimalisant l'incorporation d'un agent dans des cellules cibles
WO1996040964A2 (fr) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1993019738A1 (fr) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Methode de traitement de tissus infectes
WO1996014864A1 (fr) * 1994-11-09 1996-05-23 The Regents Of The University Of California Immunoliposomes optimalisant l'incorporation d'un agent dans des cellules cibles
WO1996040964A2 (fr) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes

Also Published As

Publication number Publication date
EP1085857A2 (fr) 2001-03-28
WO1999065461A2 (fr) 1999-12-23
AU4698499A (en) 2000-01-05
WO1999065461A9 (fr) 2001-02-01
JP2002518313A (ja) 2002-06-25
CA2335638A1 (fr) 1999-12-23

Similar Documents

Publication Publication Date Title
Ruponen et al. Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies
Choi et al. Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier
Audouy et al. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy
Midoux et al. Efficient gene transfer by histidylated polylysine/pDNA complexes
Miyata et al. Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses
Choi et al. New cationic liposomes for gene transfer into mammalian cells with high efficiency and low toxicity
ES2208936T3 (es) Complejos de lipidos cationicos-acidos nucleicos.
JP2538474B2 (ja) 生物学的活性分子の細胞内配達のための陽イオン脂質
AU776715B2 (en) Combinations for introducing nucleic acids into cells
EP0904100B1 (fr) Administration de molecules actives biologiquement, facilitee par un ligand a un recepteur et un lipide cationique
US20020065236A1 (en) CpG reduced plasmids and viral vectors
EP1832657B1 (fr) Méthylation de vecteurs plasmidiques
US20030165567A1 (en) Histidine copolymer and methods for using same
NO318180B1 (no) Preparater inneholdende nukleinsyrer.
JP2004522809A (ja) 生物学的適合遺伝子送達剤としての新規カチオンリポポリマー
US6372720B1 (en) Liposome fusion and delivery vehicle
Yockman et al. Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction
CA2246227A1 (fr) Composition pour la transfection de cellules eucaryotes superieures
AU4674101A (en) Compositions for drug delivery
JP2002316997A (ja) 目的とするアニオン性物質を細胞に導入するための複合体
AU720697B2 (en) Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
WO1999065461A3 (fr) Complexes micellaires d'amphiphiles cationiques
Boulikas et al. Histones, protamine, and polylysine but not poly (E: K) enhance transfection efficiency
Chiou et al. In vivo gene therapy via receptor-mediated dna delivery
Baru et al. Lysosome-disrupting peptide increases the efficiency of in-vivo gene transfer by liposome-encapsulated DNA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 46984/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999930442

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 554341

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2335638

Country of ref document: CA

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999930442

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999930442

Country of ref document: EP